10α-pregna-4,6-diene-3,20-dione | 601-33-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 10α-pregna-4,6-diene-3,20-dione
• 英文别名: (8S,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
• CAS: 601-33-2
• 化学式: C₂₁H₂₈O₂
• 分子量: 312.452
• InChiKey: JGMOKGBVKVMRFX-NXMWLWCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Method of preparing 9beta,10alpha-5,7-diene-steroids
  申请人：DUPHAR INTERNATIONAL RESEARCH B.V

  公开号：EP0152138A1

  公开（公告）日：1985-08-21

  The invention relates to the preparation of 9β, 10a-5,7- diene steroids by irradiating the corresponding 9a, 10β steroids with filtered ultraviolet light of an antimony lamp.

  本发明涉及用锑灯的过滤紫外线照射相应的 9a、10β 类固醇，制备 9β、10a-5,7- 二烯类固醇。
• BREAKABLE, CONTROLLED RELEASE DEVICE COMPRISING A PREFORMED PASSAGE
  申请人：Osmotica Corp.

  公开号：EP1629835A2

  公开（公告）日：2006-03-01

  The present invention provides a simple and improved osmotic device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use. One or both of the passageways optionally increases in size during use of the osmotic device. The preformed passageway and/or the second passageway increase the release rate of the active agent, enable the release of large particles containing active agent, and/or enable the release of active agents that are substantially insoluble in the environment of use. By virtue of the in situ formation of the second aperture, the device is able to release a greater overall percentage of active agent than it would release in absence of the second aperture.

  本发明提供了一种简单而改进的渗透装置，它能够首先通过一个预制通道，然后通过一个原位形成的第二通道，向使用环境中提供包含在芯中的活性剂的受控释放。在渗透装置的使用过程中，可以选择增大其中一个或两个通道的尺寸。预制通道和/或第二通道可提高活性剂的释放率，使含有活性剂的大颗粒得以释放，和/或使在使用环境中基本不溶解的活性剂得以释放。由于在原位形成了第二孔道，与没有第二孔道时相比，该装置能够释放出更大比例的活性剂。
• Screening and treatment methods for prevention of preterm delivery
  申请人：ADEZA BIOMEDICAL CORPORATION

  公开号：EP1936376A2

  公开（公告）日：2008-06-25

  Provided herein are methods, combinations, and kits for screening and treating a subject. In practicing the methods a sample, such as urine, blood, plasma, saliva, cervical fluid, vaginal fluid or a tissue sample, is obtained from a subject; if the level of a marker, such as a foetal restricted antigen or estriol, is indicative of a risk of imminent or preterm delivery, a progestational agent is administered to the subject. BY virtue of administration of the agent delivery can be delayed.

  本文提供了用于筛查和治疗受试者的方法、组合和试剂盒。在实施这些方法时，要从受试者身上获取尿液、血液、血浆、唾液、宫颈液、阴道液或组织样本等样本；如果胎儿限制性抗原或雌三醇等标记物的水平表明存在即将分娩或早产的风险，则要向受试者施用孕激素。通过使用这种药剂，可以推迟分娩。
• Classification of the oncofetal fibronection level for the indication of diseases and other conditions
  申请人：ADEZA BIOMEDICAL CORPORATION

  公开号：EP2299275A2

  公开（公告）日：2011-03-23

  A method for classifying the level of oncofetal fibronectin in a sample comprises measuring the amount of an oncofetal fibronectin indicating molecule in a sample; comparing the amount of oncofetal fibronectin indicating molecule in the sample to two or more threshold levels derived from the source of the oncofetal fibronectin and classifying the amount of oncofetal fibronectin indicating molecule in the sample according to the highest threshold level that is less than or equal to amount of the oncofetal fibronectin indicating molecule in the sample. The lower threshold may be 50 ng/ml and the higher threshold may be 150 ng/ml. A kit comprises a fibronectin or oncofetal fibronectin binding partner, a non-specific binder, a solid support containing a non-specific binding surface or a sample collection device; and a system for classifying the subject with respect to multiple thresholds.

  一种对样品中胎盘上纤维连接蛋白水平进行分类的方法，包括测量样品中胎盘上纤维连接蛋白指示分子的量； 将样本中的胎盘上纤维连接蛋白指示分子的量与从胎盘上纤维连接蛋白来源中得出的两个或多个阈值水平进行比较，并根据小于或等于样本中胎盘上纤维连接蛋白指示分子的量的最高阈值水平对样本中的胎盘上纤维连接蛋白指示分子的量进行分类。较低阈值可为 50 纳克/毫升，较高阈值可为 150 纳克/毫升。试剂盒包括纤维连接蛋白或胎盘上纤维连接蛋白结合伴侣、非特异性粘合剂、含有非特异性结合表面的固体支持物或样品收集装置；以及根据多个阈值对受试者进行分类的系统。
• Drug delivery compositions for improved stability of steroids
  申请人：Theratech, Inc.

  公开号：EP2305195A1

  公开（公告）日：2011-04-06

  A stabilized patch device for transdermal drug delivery of steroid drugs containing a 3-keto-4-en functional group is described, wherein the patch comprises an effective amount of the steroid drug and a carrier that is free of acid functional groups. The device can further contain additives such as a penetration enhancer or excipient, so long as such additives are also free of acid functional groups. The device can be either a matrix patch or a liquid reservoir patch. In a matrix patch, the carrier is a biocompatible polymeric adhesive with which the steroid drug is intimately admixed. The adhesive is preferably an acrylic polymer or copolymer. In a liquid reservoir patch, the carrier is a controlled-viscosity composition containing a thinner or thickener. Preferred steroid drugs include certain corticosteroids and sex hormones, such as progestins and androgens. A method of stabilizing such steroid drugs during storage in transdermal patches is also disclosed.

  本发明描述了一种用于透皮给药含有 3-酮-4-烯官能团的类固醇药物的稳定贴片装置，其中贴片包含有效量的类固醇药物和不含酸官能团的载体。该装置还可进一步包含添加剂，如渗透促进剂或赋形剂，只要这些添加剂也不含酸官能团即可。该装置可以是基质贴片，也可以是储液贴片。在基质贴片中，载体是一种生物相容性聚合物粘合剂，类固醇药物与之紧密混合。粘合剂最好是丙烯酸聚合物或共聚物。在储液贴片中，载体是含有稀释剂或增稠剂的可控粘度组合物。首选的类固醇药物包括某些皮质类固醇和性激素，如孕激素和雄激素。此外，还公开了一种在透皮贴剂中储存期间稳定此类类固醇药物的方法。